TBPH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Theravance Biopharma Inc (TBPH) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock lacks significant positive momentum, has neutral insider and hedge fund activity, and no recent news or catalysts to drive substantial growth. Additionally, technical indicators and options data do not suggest a compelling entry point. It is better to hold off on investing in this stock until clearer positive signals emerge.
The MACD histogram is positive at 0.0557 but contracting, indicating weakening momentum. RSI is neutral at 55.751, and moving averages are converging, suggesting no clear trend. Key support and resistance levels are close to the current price, with the pivot at 16.516, R1 at 16.76, and S1 at 16.271. Overall, the technical indicators suggest a neutral trend.
The final generic settlement with Mankind (MNKD) locks exclusivity through April 2039, removing a major overhang on the stock. Analysts have raised price targets recently, reflecting some optimism.
No recent news or significant trading activity from insiders or hedge funds. The stock has a high put-call ratio, indicating bearish sentiment in the options market. Additionally, the failure of the CYPRESS program and ongoing cost cuts may weigh on investor sentiment.
No financial data available for the latest quarter. However, previous reports indicate non-GAAP net income of $3.1MM and cash reserves of $326MM at year-end, with cost-cutting measures underway to improve cash flow.
Analysts have a mixed view with neutral ratings. B. Riley raised the price target to $17 from $14, citing the removal of overhangs, while TD Cowen raised the target to $15 from $13, noting cost-cutting measures and cash flow improvements.
